Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Weekly Repeated Intravenous Infusions in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2017
At a glance
- Drugs BI 836880 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 20 Jun 2017 Planned End Date changed from 29 Nov 2017 to 29 Jul 2018.
- 20 Jun 2017 Planned primary completion date changed from 29 Nov 2017 to 29 Jul 2018.
- 20 Apr 2016 Status changed from not yet recruiting to recruiting.